Zha M, Li F, Xu W, Chen B, Sun Z (2014) Isolation and characterization of islet stellate cells in rat
This observation suggests that abnormal EAT mass may act as a driving factor in the early pathophysiological process of AF rather than a concomitant consequence of late LA structural remodeling (characterized by increased LA volume) (82)
Timeline recommendations by previous dose For those coming off low-dose tirzepatide (2.5 to 5mg), a 20 to 25 day washout is generally sufficient
The most frequent adverse effects are gastrointestinal and dose-related: Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort - Typically worst during dose escalation and often resolve or attenuate with continued treatment and slower titration
Funding This work was supported by a R01MH128311 and a R56MH125895 to CN
IV treatments are more direct but also carry more risks